Tirzepatide Reconstitution and Dosing Guide

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide that has shown significant effects on glucose metabolism and body composition in research settings. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing effects on appetite regulation, insulin sensitivity, and metabolic rate in test subjects. It is available as a lyophilized research peptide in 5mg, 10mg, 15mg, and 30mg vials. For research purposes only.

For a 10mg vial: Add 2mL bacteriostatic water = 5mg/mL (50 mcg per unit on U-100 syringe) • 2.5mg dose = 50 units (0.5mL) • 5mg dose = 100 units (1mL) — requires full 1mL syringe For a 30mg vial: Add 2mL bacteriostatic water = 15mg/mL (150 mcg per unit) • 2.5mg dose = 16.7 units (round to 17 units) • 5mg dose = 33 units • 7.5mg dose = 50 units • 10mg dose = 67 units • 12.5mg dose = 83 units • 15mg dose = 100 units The 30mg vial with 2mL is the most cost-effective option for research protocols, as it provides multiple weeks of doses from a single reconstitution.

Current official Tirzepatide prescribing information uses 2.5 mg once weekly for the first 4 weeks, followed by 5 mg once weekly. The 2.5 mg step is an initiation dose rather than a maintenance dose. After the 5 mg step, any increase is by 2.5 mg only after at least 4 weeks at the current dose. Dose increases are not automatic: the selected maintenance dose should reflect response and tolerability in the patient under clinical care. Labelled maintenance options for weight management are 5 mg, 10 mg, or 15 mg once weekly, with 15 mg as the maximum. A schedule that changes from 1 mg to 1.5 mg, 2 mg, and 2.5 mg in consecutive weeks is not the labelled Tirzepatide titration schedule. Source: https://pi.lilly.com/us/zepbound-uspi.pdf

Route: Subcutaneous injection Frequency: Once weekly, on the same day each week Timing: Any time of day, with or without food Injection sites: Abdomen, thigh, or upper arm — rotate weekly Needle: U-100 insulin syringe, 29-31 gauge Important: If a dose is missed, administer it as soon as possible within 4 days of the missed day. If more than 4 days have passed, skip the missed dose and resume on the next scheduled day. Do not double-dose.

For lyophilised and reconstituted tirzepatide research material, use the exact supplier label, formulation documentation and lot-specific COA for temperature, light protection, expiry and discard timing. Do not assume a generic research vial shares the storage profile of a commercial prefilled medicine, and do not treat bacteriostatic water as proof of a universal 28-day shelf life.